Enterprise Value

2.171B

Cash

356.2M

Avg Qtr Burn

-96.07M

Short % of Float

27.21%

Insider Ownership

0.54%

Institutional Own.

89.22%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Iovance TIL (LN-145) Details
Non-small cell lung carcinoma, Cancer

Phase 2

Data readout

Iovance TIL (LN-145) or lifileucel +/- pembrolizumab Details
Cancer, Non-small cell lung carcinoma, Melanoma

Phase 2

Update

Lifileucel Details
Cancer, Cervical cancer

Phase 2

Update

Iovance TIL (LN-145) Details
Cancer, Endometrial cancer

Phase 2

Initiation

IOV-4001 Details
Non-small cell lung carcinoma, Cancer, Melanoma

Phase 1/2

Update